We provide you with 20 years of free, institutional-grade data for ABUS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ABUS. Explore the full financial landscape of ABUS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Sims Karen | Initial | 2023-07-12 |
The information provided in this report about ABUS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Arbutus Biopharma Corporation(NASDAQ:ABUS) 
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-del...
Website: http://www.arbutusbio.com
Founded: 2007
Full Time Employees: 78
CEO: William Bill Collier
Sector: Healthcare
Industry: Biotechnology